Anne E. Kingston - 10 Apr 2026 Form 4 Insider Report for PROTHENA CORP PUBLIC LTD CO (PRTA)

Reporting relationship: Chief Strategy Officer
Issuer ticker: PRTA
Reported as of: 10 Apr 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 10 Apr 2026, 19:22:05 UTC
Next SEC filing: 30 Jul 2026
Source filing: View source filing
Reporting owner signature: /s/ Michael J. Malecek, as Attorney-in-Fact for Anne E. Kingston

Key filing fact

Anne E. Kingston filed Form 4 for PROTHENA CORP PUBLIC LTD CO (PRTA) on 10 Apr 2026.

Key facts

This page summarizes Anne E. Kingston's Form 4 filing for PROTHENA CORP PUBLIC LTD CO (PRTA).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 10 Apr 2026, 19:22.

Change

No earlier filing in this sequence is available for direct comparison.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0002127851 Primary reporting owner

Kingston Anne Evans

Relationship: Chief Strategy Officer
Address: C/O PROTHENA BIOSCIENCES INC, 1800 SIERRA POINT PARKWAY, BRISBANE
Signature: /s/ Michael J. Malecek, as Attorney-in-Fact for Anne E. Kingston
Signature date: 10 Apr 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

PRTA transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value
Shares: +100,000
Change %
Price: $0.000000^*
Shares after: 100,000
Date: 10 Apr 2026
Ownership: Direct
Underlying class: Ordinary Shares
Underlying amount: 100,000
Exercise price: $10.50
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The shares subject to the option will vest and become exercisable as to 25% of the total number of shares subject to the option on April 10, 2027, and with respect to 1/48th of the total number of shares subject to the option in successive, equal monthly installments on each monthly anniversary thereafter, subject to the Reporting Person's continued employment with the Issuer on each such vesting date.